Original assessment ยท live

MCD: Hold + Add

Published 11 Sep 2026, 18:34 BST. This is the frozen version, not the current recommendation.

Target$338.52
Target date2027-09-11
Price known at publication$255.692026-09-04

Why this assessment was issued

Stored financial statements changed; the revised figures need checking. The model version changed. The published model version has been replaced. Record the new calculation basis even if the rating is unchanged. The valuation supports a measured positive view, but the full Buy requirements are not met. Review borrowing.

The valuation supports a measured positive view, but the full Buy requirements are not met. Review borrowing.

Supporting evidence

Year-to-date profit has improved

Across 2 completed quarters since 2025-12-31, net income was 4,345.0m versus 4,121.0m in the matching prior-year periods (USD). Check whether the latest quarter changes that direction.

Quarterly sales are growing

Revenue changed +3.7% from the same quarter last year, through 2026-06-30. The previous quarterโ€™s year-on-year change was +9.4%.

Opposing evidence

Capital spending changes the cash picture

Operating cash covers 1.29 times profit, but cash after capital spending covers 0.88 times. Cash generation is stronger before the investment bill is paid.

The profit margin narrowed

The latest quarterly operating margin was 47.0%, -0.2 percentage points from a year earlier. Compare the sales and margin contributions below.

The original scenarios

ScenarioSales growthProfit marginModel value
Weaker1.6%28.6%$258.85
Central6.6%31.8%$338.52
Stronger11.6%35.0%$432.76

Method: Earnings and historical valuation. A sufficiently complete, positive earnings record allows the stock's own P/E history to be used. These scenarios are not probability intervals.

Original assumptions and checks
eps12.55
cash822000000.0
debt54592000000.0
years1.1991786447638604
growth6.580061225449185
margin31.718586434682166
profit8787000000.0
cash_okTrue
debt_okFalse
growths[2.982685872253743, 9.721352536005012, 9.419073203492268, 3.741049247406103]
revenue27703000000.0
downside0
leverage3.568015925680159
multiple24.93718592964824
free_cash7761000000.0
buy_hurdle15
volatility16.047288847418912
history_end2026-09-04
reward_riskNot available
annual_years5
usable_weeks157
history_start2023-09-08
history_weeks157
financial_date2026-06-30
interest_cover7.879384615384615
operating_cash11344000000.0
uncapped_growth6.580061225449185
current_multiple20.37370517928287
projected_margin31.78453033841231
historical_margin31.850474242142457

Recent price ยท Passed. Weekly close dated 2026-09-04.

Suitable business model ยท Passed. Value operating cash flow or comparable earnings; deduct debt and other ownership claims where appropriate.

Four quarters ยท Passed. Four quarters ending 2026-06-30.

Current financials ยท Passed. Statements through 2026-06-30; factor prices dated 2026-09-04.

Annual record ยท Passed. 5 consecutive annual profit margins, including loss years.

Comparable earnings history ยท Passed. P/E is usable in 157 of 157 weeks. At least 52 usable weeks and 70% coverage are required; excluding too many loss or missing weeks would bias the target.

Earnings and price dates ยท Passed. Earnings-release EPS $12.55, for four quarters ending 2026-06-30.

Price risk ยท Passed. Risk uses the latest 52 weekly price changes.

Comparable sales growth ยท Passed. Growth uses the median of four quarterly year-on-year comparisons.

Positive statement earnings ยท Passed. Trailing statement profit is positive.

Earnings reconciliation ยท Passed. Release EPS is $12.55; statement-derived EPS is $12.42. The difference is within the 5% review threshold; this does not prove there are no unusual items.

Statement totals ยท Passed. The latest four quarters agree with the trailing snapshot within 5%.

Cash and borrowing ยท Passed. Cash generation, debt and interest-cover figures are available.

Target publication review ยท Passed. The model estimate is within SM's automatic publication range of one quarter to four times the current price. This is a review threshold, not evidence that the market price is correct.

Policy sm-review-2-research ยท Model sm-assessment-9-financial-integrity ยท Data 00417eeedc67.

Open current research โ†—

Evidence context